Cannabis company Creso Pharma COPHF’s wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc. shared promising early findings on its ongoing Phase 2 clinical trial assessing the efficacy of psilocybin on treatment-resistant PTSD. The single-a…